Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD

Conclusions This first study of MART in COPD found that budesonide/formoterol MART might be similarly effective to fluticasone/salmeterol fixed-dose therapy in moderate to severe patients with COPD, at a lower daily ICS dosage. Further evidence is needed about long-term safety.

http://thorax.bmj.com/cgi/content/short/78/5/451?rss=1

Source: Thorax - April 13, 2023 Category: Respiratory Medicine Authors: Muiser, S., Imkamp, K., Seigers, D., Halbersma, N. J., Vonk, J. M., Luijk, B. H. D., Braunstahl, G.-J., van den Berg, J.-W., Kroesen, B.-J., Kocks, J. W. H., Heijink, I. H., Reddel, H. K., Kerstjens, H. A. M., van den Berge, M. Tags: Thorax Chronic obstructive pulmonary disease Source Type: research